|Bid||21.75 x 200|
|Ask||22.00 x 200|
|Day's Range||21.70 - 23.20|
|52 Week Range||4.01 - 27.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.50|
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / The Federal Reserve announced it would be raising interest rates by 25 basis points. Shortly after the Fed's announcements, stocks hit the session highs. However, ...
Glancy Prongay & Murray LLP announces an investigation on behalf of Sangamo Therapeutics, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
The latest earnings release Sangamo Therapeutics Inc’s (NASDAQ:SGMO) announced in December 2017 revealed company earnings became less negative compared to the previous year’s level as a result of recent tailwindsRead More...
RICHMOND, Calif. , March 5, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Dr. Sandy Macrae , CEO of Sangamo, is scheduled to participate in the following healthcare ...
RICHMOND, Calif., March 2, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant effective ...
Sangamo Therapeutics Inc (NASDAQ:SGMO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Stock Monitor: Corcept Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 02, 2018 / Active-Investors.com has just released a free research report on Sangamo Therapeutics, Inc. (NASDAQ: ...
RICHMOND, Calif., Feb. 28, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom has granted the Clinical Trial Authorisation (CTA) for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating SB-FIX, a zinc finger nuclease (ZFN)-mediated in vivo genome editing treatment for hemophilia B. The CTA allows for initiation of Europe's first in vivo genome editing study. Once preliminary safety and efficacy have been demonstrated in the ongoing SB-FIX Phase 1/2 clinical trial in adults (18 years or older), Sangamo may then begin enrolling adolescents (12 – 17 years of age) into the study.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
M&A and deal-making exploding in cell therapy space, demonstrating how important this field will be in the coming 30 to 50 years. Sangamo (SGMO) is the most recent example, with $3 billion deal with ...
NEW YORK, Feb. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Coherent, ...
Sangamo rocketed north of 10% in premarket trading Thursday after landing a deal with Gilead to collaborate on cancer treatments.
The deal is the latest by a major drugmaker looking to develop lucrative gene therapies that have the potential to treat ailments by directly targeting disease-causing genes. Shares of California biotech firm Sangamo jumped more than 20 percent to a 17-year high of $27.30 on Thursday morning. "These are indeed exciting times in the field of genome-editing and gene therapy," Sangamo Chief Executive Officer Sandy Macrae said on a call with analysts.
Gilead Sciences Inc.'s unit Kite has entered an agreement with Sangamo Therapeutics Inc. to collaborate in developing engineered cell therapies to treat cancer. Under the terms of the deal, Kite will use ...
Company Also Separately Announced Collaboration with Kite, a Gilead Company, to Develop Next-Generation Engineered Cell Therapies for the Treatment of Cancer Conference Call and Webcast at 8:00 a.m. Eastern ...